Mark Lakshmanan
0000-0002-6578-9570
Publication & Citation Trends
Publications
80 total
Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis. OA
Cited by 10
Semantic Scholar
A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes OA
Cited by 12
Semantic Scholar
Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial. OA
Cited by 4
Semantic Scholar
725-P: Protein Biomarkers Associated with Dulaglutide and Cardiovascular Events in REWIND
Cited by 0
Semantic Scholar
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial
Cited by 32
Semantic Scholar
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND OA
Cited by 46
Semantic Scholar
Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial OA
Cited by 19
Semantic Scholar
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.
Cited by 35
Semantic Scholar
Research Topics
Diabetes Treatment and Management
(37)
Metabolism, Diabetes, and Cancer
(26)
Diabetes Management and Research
(8)
Pharmacology and Obesity Treatment
(8)
Estrogen and related hormone effects
(7)
Affiliations
University of Maryland, Baltimore
National Institutes of Health
Eli Lilly (United States)
Indianapolis Zoo
National Institute of Diabetes and Digestive and Kidney Diseases